One of the downsides of rapamycin is that it can activate myrostatin. What I find interesting is that sulforaphane inhibits myrostatin, at least in pigs.
https://www.ncbi.nlm...pubmed/23092945
However, sulforaphane still activates AMPK and NRF2. This would provide some of the same autophagy, mitochondrial, and antioxidant benefits.
So these questions come to mind.
1) Which is the most potent substance at inducing AMPK, sulforaphane or rapamycin?
2) If rapamycin is the most potent substance at inducing AMPK, is there a drawback to blocking myrostatin at the same time?
3) Other than supplementing sulforaphane at the same time, are there any other strategies to block the increase in myrostatin from rapamycin?
Sorry it took so long to answer. First, be aware that, with drugs like Rapamycin, the side effects at high, chronic doses are sometimes the opposite of their effects at low and intermittent doses. I don't know if that's the case for myostatin, but I can't seem to find any study result that says either way.
This might be unrelated, but to deal with inflammation being caused by microglia mistakenly and fruitlessly attacking misfolded proteins, a MD who has been mentioned several times by several people, has suggested that taking Cardesartan might be a good choice, It's a high blood pressure drug that's been around awhile. A new study is here: https://www.dddmag.c...kinson’s-effect and here: http://stke.sciencemag.org/content/8/376/ra45.full.pdf+html
At least that's my interpretation of what the study is saying.
Just found this study which, at first glance, might be useful in a discussion about myostatin: https://www.ncbi.nlm...pubmed/23868687
"Nonfunctional overreaching" sounds familiar. Not sure about any of this. Can you quote a study?
Edited by Jaris, 24 January 2017 - 02:29 AM.